Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)

Robert GoodnoughCalifornia Poison Control System San Francisco Division, San Francisco, CA, USA; ;Department of Emergency Medicine, University of California San Francisco, San Francisco, CA, USA; Correspondence[email protected]

http://orcid.org/0000-0001-5333-087X

Mariko NomuraDepartment of Emergency Medicine, Alameda Health System-Highland Hospital, Oakland, CA, USA;

Adina BadeaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;

Kara L. LynchDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;

Neal L. BenowitzDepartments of Medicine and Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA

Ben TsutaokaDepartment of Emergency Medicine, University of California San Francisco, San Francisco, CA, USA;

"Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)." Clinical Toxicology, 57(11), pp. 1123–1124

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)

Information for

Open access

Opportunities

Help and information

Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day)

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature